Main Street Financial Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Main Street Financial Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-609	Closed	-$239K	–	645
2025 Q3	$239K	Buy	+609	New	+$255K	0.02%	546
2025 Q2	–	Sell	-434	Closed	-$210K	–	582
2025 Q1	$210K	Buy	+434	New	+$202K	0.02%	476
2024 Q3	–	Sell	-2,699	Closed	-$1.27M	–	584
2024 Q2	$1.27M	Buy	2,699 +381	+16%	+$165K	0.12%	158
2024 Q1	$969K	Buy	+2,318	New	+$980K	0.1%	187
2023 Q4	–	Sell	-596	Closed	-$207K	–	493
2023 Q3	$207K	Buy	596 +11	+2%	+$3.85K	0.03%	427
2023 Q2	$206K	Buy	+585	New	+$197K	0.03%	423
2022 Q2	–	Sell	-3,691	Closed	-$963K	–	498
2022 Q1	$963K	Buy	3,691 +64	+2%	+$15.2K	0.14%	152
2021 Q4	$796K	Buy	3,627 +1,616	+80%	+$314K	0.11%	179
2021 Q3	$365K	Buy	2,011 +105	+6%	+$20.5K	0.06%	321
2021 Q2	$384K	Buy	1,906 +666	+54%	+$139K	0.06%	298
2021 Q1	$266K	Sell	1,240 -274	-18%	-$60.2K	0.05%	349
2020 Q4	$358K	Buy	+1,514	New	+$347K	0.07%	256

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Main Street Financial Solutions's VRTX Position: Q4 2025 in Review

Main Street Financial Solutions sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 609 shares — an estimated $239K sold.

Main Street Financial Solutions first reported a position in VRTX in Q4 2020 and held it in 12 quarters. The position peaked at $1.27M in Q2 2024. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Main Street Financial Solutions reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Main Street Financial Solutions sold 609 Vertex Pharmaceuticals shares in Q4 2025, an estimated $239K.
Main Street Financial Solutions first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 12 quarters.
Main Street Financial Solutions's Vertex Pharmaceuticals position peaked at $1.27M in Q2 2024.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Main Street Financial Solutions's 13F filing for Q4 2025, filed 17 Feb 2026.